BioNexus Gene Lab Corp. (BGLC) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
BGLC Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, BioNexus Gene Lab Corp. (BGLC) trades at a price-to-earnings ratio of -2.3x, with a stock price of $2.06 and trailing twelve-month earnings per share of $-1.28.
The current P/E is 100% below its 5-year average of 6588.3x. Over the past five years, BGLC's P/E has ranged from a low of 4197.6x to a high of 10913.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, BGLC trades at a 110% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, BGLC trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BGLC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BGLC P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $44B | 42.8 | 3.00Best | +23%Best | |
| $173B | 26.2Lowest | 12.41 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BGLC Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q2 | $136.90 | $0.02 | 7360.2x | +12% | |
| FY2022 Q1 | $205.30 | $0.03 | 6798.0x | +3% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $255.70 | $0.05 | 4852.0x | -26% |
| FY2021 Q3 | $141.70 | $0.03 | 5408.4x | -18% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $138.10 | $0.03 | 4197.6x | -36% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $252.10 | $0.02 | 10913.4x | +66% |
Average P/E for displayed period: 6588.3x
See BGLC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BGLC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BGLC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
Is BGLC stock overvalued or undervalued?
BGLC trades at -2.3x P/E, below its 5-year average of 6588.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BGLC's valuation compare to peers?
BioNexus Gene Lab Corp. P/E of -2.3x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is BGLC's PEG ratio?
BGLC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.